Penserra Capital Management LLC increased its position in Danaher Co. (NYSE:DHR) by 355.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,135 shares of the conglomerate’s stock after buying an additional 15,711 shares during the quarter. Penserra Capital Management LLC’s holdings in Danaher were worth $2,187,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Danaher by 10.3% in the second quarter. FMR LLC now owns 21,011,026 shares of the conglomerate’s stock valued at $2,073,369,000 after buying an additional 1,963,116 shares during the period. Putnam Investments LLC increased its stake in shares of Danaher by 0.8% in the second quarter. Putnam Investments LLC now owns 6,385,003 shares of the conglomerate’s stock valued at $630,072,000 after buying an additional 51,596 shares during the period. Flossbach Von Storch AG increased its stake in shares of Danaher by 3.2% in the third quarter. Flossbach Von Storch AG now owns 5,729,830 shares of the conglomerate’s stock valued at $622,603,000 after buying an additional 180,025 shares during the period. Findlay Park Partners LLP increased its stake in shares of Danaher by 4.8% in the second quarter. Findlay Park Partners LLP now owns 3,825,000 shares of the conglomerate’s stock valued at $377,451,000 after buying an additional 175,000 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Danaher by 11.5% in the third quarter. American Century Companies Inc. now owns 3,060,583 shares of the conglomerate’s stock valued at $332,563,000 after buying an additional 316,307 shares during the period. 76.80% of the stock is owned by institutional investors.

DHR has been the topic of several analyst reports. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $119.00 target price on the stock in a report on Wednesday, September 19th. Morgan Stanley upped their target price on Danaher from $122.00 to $126.00 and gave the company an “overweight” rating in a report on Wednesday, October 10th. Bank of America set a $113.00 target price on Danaher and gave the company a “buy” rating in a report on Thursday, July 19th. Royal Bank of Canada upped their target price on Danaher to $107.00 and gave the company a “positive” rating in a report on Thursday, July 19th. They noted that the move was a valuation call. Finally, Robert W. Baird reduced their target price on Danaher from $116.00 to $114.00 and set an “outperform” rating on the stock in a report on Friday, October 19th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $112.14.

In other Danaher news, insider William King sold 53,433 shares of the stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $101.64, for a total transaction of $5,430,930.12. Following the transaction, the insider now directly owns 36,425 shares in the company, valued at approximately $3,702,237. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Daniel L. Comas sold 36,000 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $103.88, for a total value of $3,739,680.00. Following the transaction, the chief financial officer now owns 124,218 shares in the company, valued at $12,903,765.84. The disclosure for this sale can be found here. Insiders have sold a total of 150,007 shares of company stock worth $15,202,163 over the last 90 days. Company insiders own 11.90% of the company’s stock.

Shares of DHR stock opened at $104.39 on Friday. Danaher Co. has a one year low of $91.65 and a one year high of $110.13. The company has a market capitalization of $72.94 billion, a P/E ratio of 25.90, a P/E/G ratio of 2.00 and a beta of 1.04. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 18th. The conglomerate reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The firm had revenue of $4.85 billion for the quarter, compared to analysts’ expectations of $4.80 billion. Danaher had a return on equity of 11.59% and a net margin of 14.07%. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.00 EPS. As a group, sell-side analysts anticipate that Danaher Co. will post 4.51 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 26th. Shareholders of record on Friday, September 28th were issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend was Thursday, September 27th. Danaher’s payout ratio is 15.88%.

WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/11/10/penserra-capital-management-llc-purchases-15711-shares-of-danaher-co-dhr.html.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.